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LETTERS TO THE EDITORKNOWING THE COST OF
CARDIAC SURGICAL
COMPLICATIONS: DOES IT
REALLY REDUCE THEM OR
IMPROVE QUALITY?
To the Editor:
I read with interest the article by
Christensen and colleagues1 about
the incremental costs of postoperative
hemorrhage in cardiac surgery, a com-
mon complication. I agree with the
authors that measures to prevent or de-
crease postoperative hemorrhage are
important in cost-effectiveness. In
fact, all cardiac surgical complications
are associated with substantial added
cost, as shown in several articles.2
Cardiac surgery has its own special
peculiarities that make it different
from any other kind of surgery. It has
the widest spectrum of complications,
most of them are fatal. With regard to
the etiology of postoperative hemor-
rhage, a great deal is attributable to
the vast array of antiplatelet and
thrombolytic agents given before sur-
gery by referring cardiologists. Most
other causes mentioned by Christen-
sen and colleagues1 are usually un-
avoidable.
It is difficult to calculate the exact
cost of each individual complication,
because complications usually start
as one kind and rapidly move on to
another in a cascade pattern, ending
this vicious circle with multiorgan
failure and death. Postoperative renal
failure necessitating hemodialysis,
prolonged need for ventilation, and
mediastinitis are among the most ex-The Editor welcomes submissions for possible publica-
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The Journalpensive complications, by far exceed-
ing the cost of bleeding. All these
complications deserve preventive
measures, but because of their harm-
ful effects on the patients rather than
for cost containment.
Avoiding complications is much
better than handling and overcoming
them. Careful selection of patients
who will benefit most with the least
trouble is the criterion standard of the
ideal patient. Quality improvement in
this multidisciplinary and delicate ser-
vice requires a comprehensive under-
standing of the basics and details of
the surgical procedures, not the incre-
mental costs of complications.
Morbidity and mortality can not be
‘‘priced’’ financially, because there is
no winner in this deal. Both the patient
and the health service are losers.
Knowing the added cost will never re-
duce the complications. Death, the
most disastrous complication, is actu-
ally the cheapest, with no extra cost
to be paid. In a series from my own
group,3 lifelong hemodialysis was the
most expensive complication, fol-
lowed by a patient being ‘‘stuck’’ on
the ventilator.
The most important feature of car-
diac surgery is that only a certain sub-
set of cardiac patients, according to
clinical guidelines, will benefit from
surgery. All cardiac procedures, ex-
cept patent ductus arteriosus ligation,
are palliative. The ongoing atheroscle-
rosis progression will sooner or later
‘‘block’’ the grafts. Valve replace-
ment, as the name implies, actually
replaces one disease condition with
another. The concept of ‘‘do no
harm’’ must be exercised with every
cardiac patient. Health care providers
must avoid complications because of
this concept, not because of extra
cost. Candidates at very high risk
who will receive only marginal surgi-
cal benefit should not undergo surgery.
Cardiac patients must be considered
according to the indication and type
of surgical procedure and assessed ac-
cording to the international risk stratifi-
cation scores. Strict adherence toof Thoracic and Cardiovascular Surgerevidence-basedmedicine must be rein-
forced and practiced by the referring
cardiologist, cardiac anesthetist, perfu-
sionist, surgical team, and intensive
care staff. A successful cardiac proce-
dure is the outcome of perfect perfor-
mance by all these team members in
conjunction with the previously men-
tioned patient factors.
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We naturally agree with Dr Al-
Ebrahim that avoiding complications
in cardiac surgery is far better than treat-
ing themas theyoccur; however,webe-
lieve that some key messages of our
research have been misunderstood. Dr
Al-Ebrahim states, ‘‘Quality improve-
ment in this multidisciplinary and deli-
cate service requires comprehensive
understanding of the basics and details
of the surgical procedures, and the in-
cremental costs of complications. Mor-
bidity and mortality can not be
‘‘priced’’ financially, because there is
no winner in this deal. Both the patient
and the health service are losers. Know-
ing the added cost will never reduce the
complications. Death, the most disas-
trous complication, is actually the
cheapest, with no extra cost to be
paid.’’ Although it is correct that mor-
bidity and mortality cannot be priced,
the costs of treating medicaly c Volume 139, Number 6 1667
Letters to the Editorcomplications and even of saving lives
can certainly be estimated.1 Indeed,
the very cornerstone of the health eco-
nomic discipline is to do exactly such
estimations across the most common
diseases to determine how limited
health care resources can be used most
effectively to benefit the most patients.
Knowing the economic consequences
of medical complications is a highly es-
sential step in our efforts to identify
cost-effective clinical interventions to
address them. In health care systems
with limited resources, policy makers,
health insurers, hospital administrators,
and practicing physicians need to con-
sider carefully the cost-effectiveness
of medical interventions, both in the
daily practice of medicine and as part
of long-term evaluation and planning
of quality improvement initiatives.
As we describe in our article, medi-
cal interventions can either be cost
saving (if the hospital’s cost savings
are greater than the cost of the inter-
vention), cost-effective (when the
incremental cost of a clinical interven-
tion is reasonable with regard to the
clinical benefits obtained), or cost en-
hancing (if the clinical intervention in-
duces higher hospital costs without
any clinical benefit). In the context of
excessive hemorrhage in cardiac sur-
gery, knowledge of the medical and
economic consequences of this com-
plication is the very first step in the
identification of safe, effective, and
cost-effective clinical interventions to
address this complication. Addition-
ally, awareness of the costs of exces-
sive hemorrhage may compel health
care professionals to apply preventive
and therapeutic measures as early as
possible. In our research we used sim-
ple and objective criteria for excessive
postoperative hemorrhage to allow
early identification of patients at risk
for severe morbidity or even a fatal
outcome. Early identification of bleed-
ing facilitates early treatment and
thereby improves outcome. This is
the very basis for improvement in
clinical care and applied quality im-
provement.1668 The Journal of Thoracic andOf course, health care providers
must primarily keep the individual pa-
tient’s health in mind. In addition,
however, we need to be aware of the
costs of complications to provide the
highest standard of care for all pa-
tients. This may be even more impor-
tant in the future, when rationing of
health care resources is likely to
become an even more dominant part
of our health care services.
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PERCUTANEOUS CORONARY
INTERVENTION INCREASE
THE RISK OF GRAFT FAILURE
IN SUBSEQUENT CORONARY
SURGERY?
To the Editor:
We recently pointed out1 that there
is no evidence to support significantly
better angiographic patency with ra-
dial artery conduit than with saphe-
nous vein graft in coronary arteryCardiovascular Surgery c June 2010bypass grafting in controlled, random-
ized trials reported to date. We do not,
however, support inclusion of data ex-
tracted from the article by Gaudino
and associates2 in the recently pub-
lished meta-analysis by Benedetto
and colleagues3 of controlled, random-
ized trials comparing radial artery con-
duits and saphenous vein grafts with
respect to angiographic patency.
The article by Gaudino and associ-
ates2 reported 2 controlled, random-
ized trials including patients with
previous percutaneous stent implanta-
tion (in any coronary vessel) with pre-
operative angiographic confirmation
of a failed (I trial) or patent (II trial) in-
tracoronary stent. In that report,2 they
focused on the results of arterial versus
venous grafts directed to the first ob-
tuse marginal artery. There were, how-
ever, no data on failed stent location.
In a subsequent analysis4 of that initial
report, Gaudino and coworkers4 fo-
cused on the complementary venous
grafts to nonobtuse target coronary
vessels (right coronary artery and
circumflex artery other than the first
obtuse marginal artery). They con-
cluded that patients with development
of in-stent restenosis face a higher risk
of early venous graft failure (46 oc-
cluded of 84, patency rate 45.2% at
5 years after surgery). Even in that ar-
ticle, however, there were no precise
data about the number of failed venous
grafts that were distributed to targeted
coronary arteries with in-stent resteno-
sis. We were able to find out only that
25 of the failed stents were located on
a circumflex artery other than the first
obtuse marginal artery, 31 were lo-
cated on the right coronary artery,
and 7 were located on the left anterior
descending coronary artery. Although
43 venous graft–targeted vessels
were circumflex artery other than the
first obtuse marginal artery and 41
were right coronary artery, we must
face the possibility that the vast major-
ity of venous grafts were placed on
previously stented coronary arteries.
It has been argued by Gaudino and
associates2,4 that in-stent restenosis is
